Renal and cardiovascular events: do they deserve the same consideration in clinical trials?

被引：3
|
作者：
Ruilope, Luis M. [1 ]
Segura, Julian [1 ]
Fujita, Toshiro [2 ]
Ritz, Eberhard [3 ]
机构：
[1] Hosp 12 Octubre, Hypertens Unit, Dept Nephrol, E-28041 Madrid, Spain
[2] Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo, Japan
[3] Ruperto Carola Univ Heidelberg, Div Nephrol, Dept Internal Med, Heidelberg, Germany
来源：
JOURNAL OF HYPERTENSION | 2009年 / 27卷 / 09期
关键词：
RANDOMIZED CONTROLLED-TRIAL; KIDNEY-DISEASE; BLOOD-PRESSURE; OUTCOMES; RISK; PERINDOPRIL; NEPHROPATHY; MULTICENTER; RATIONALE; RAMIPRIL;
D O I：
10.1097/HJH.0b013e32832e0b19
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：1743 / 1745
页数：3
相关论文
共 50 条
  • [31] Pharmacogenomics in cardiovascular clinical trials
    Shah, R
    Darne, B
    Atar, D
    Abadie, E
    Adams, KF
    Zannad, F
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (06) : 705 - 708
  • [32] Clinical cardiovascular trials of HRT
    Siseles, N.
    Berg, G.
    [J]. GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2012, 34 (01): : 79 - 81
  • [33] Consideration of Ayurvedic diagnostics in design of clinical trials
    Manohar, P. Ram
    [J]. ANCIENT SCIENCE OF LIFE, 2013, 33 (01) : 1 - 3
  • [34] Consideration of ethical issues in the design of clinical trials
    Weymuller, EA
    [J]. AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1996, 17 (01) : 2 - 11
  • [35] Effects of exenatide BID on renal function and adverse events in Phase III clinical trials
    Tuttle, K.
    Brown, C.
    Bonnard, C.
    Shenouda, S.
    Heilmann, C.
    Hoogwert, B.
    Anderson, P. W.
    [J]. DIABETES & METABOLISM, 2012, 38 : A97 - A97
  • [36] How do breast cancer clinical trials approach cardiovascular safety: targeted or generalized?
    Hamid, Arsalan
    Fonarow, Gregg C.
    Butler, Javed
    Hall, Michael E.
    [J]. CARDIO-ONCOLOGY, 2024, 10 (01)
  • [37] How do breast cancer clinical trials approach cardiovascular safety: targeted or generalized?
    Arsalan Hamid
    Gregg C. Fonarow
    Javed Butler
    Michael E. Hall
    [J]. Cardio-Oncology, 10
  • [38] The Glycemia-Cardiovascular Disease Hypothesis DO RECENT CLINICAL TRIALS RESOLVE THE QUESTION?
    Simons-Morton, Denise G.
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2008, 1 (03): : 185 - 186
  • [39] Hop, Skip, and Jump Do We Need Phase II Cardiovascular Clinical Trials?
    O'Connor, Christopher M.
    [J]. JACC-HEART FAILURE, 2015, 3 (03)
  • [40] Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?
    Nazanin Aghel
    Diego Hernan Delgado
    Jeffrey Howard Lipton
    [J]. Leukemia, 2018, 32 : 2095 - 2104
12345